Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies

Clinical Cancer Research

Volumn 24, Issue 15, 2018, Pages 3539-3549

  Odegaard, Justin I ^a   Vincent, John J ^a   Mortimer, Stefanie ^a   Vowles, James V ^a   Ulrich, Bryan C ^b   Banks, Kimberly C ^a   Fairclough, Stephen R ^a   Zill, Oliver A ^a,c   Sikora, Marcin ^a   Mokhtari, Reza ^a   Abdueva, Diana ^a   Nagy, Rebecca J ^a   Lee, Christine E ^a   Kiedrowski, Lesli A ^a   Paweletz, Cloud P ^b   Eltoukhy, Helmy ^a   Lanman, Richard B ^a   Chudova, Darya I ^a   Talasaz, AmirAli ^a  

^a Guardant Health   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE NUCLEIC ACID; CIRCULATING TUMOR DNA; TUMOR MARKER;

ALLELE; ARTICLE; CANCER GENETICS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA SEQUENCE; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FEASIBILITY STUDY; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL RECORD; NON SMALL CELL LUNG CANCER; PATIENT CARE; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; FEMALE; GENETICS; GENOMICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; MALE; MUTATION; NEOPLASM; PATHOLOGY;

BIOMARKERS, TUMOR; CELL-FREE NUCLEIC ACIDS; CIRCULATING TUMOR DNA; FEMALE; GENOMICS; GENOTYPE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MUTATION; NEOPLASMS;

EID: 85051124630     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-3831     Document Type: Article

References (51)

1. Henk HJ, Ray S. Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer. Lung Cancer Manag 2013;2:189-97.
2. Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K,Diebold J, PietriniM, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol 2016;11:1846-55.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology [Internet]. Fort Washington, PA: NCCN. Available from: https://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site.
4. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. NCCN Non-Small Cell Lung Cancer Guidelines (Version 4.2017) [Internet]. Fort Washington, PA: NCCN. Available from: http://www. nccn.org/professionals/physician-gls/pdf/nscl.pdf.
5. Lokhandwala T, Bittoni MA, Dann RA, D'Souza AO, Johnson M, Nagy RJ, et al. Costs of diagnostic assessment for lung cancer: a medicare claims analysis. Clin Lung Cancer 2017;18:e27-34.
6. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, BlackWC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
7. Anzidei M, Sacconi B, Fraioli F, Saba L, Lucatelli P, Napoli A, et al. Development of a prediction model and risk score for procedure-related complications in patients undergoing percutaneous computed tomography-guided lung biopsy. Eur J Cardiothorac Surg 2015;48:e1-6.
8. Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 2016;22:5772-82.
9. Villaflor V,WonB, Nagy R, Banks K, Lanman RB, Talasaz A, et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget 2016;7:66680-891.
10. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 2015;121:631-9.
11. Gutierrez ME, Choi K, Lanman RB, Licitra EJ, Skrzypczak SM, Pe Benito R, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer 2017;18:651-9.
12. Ruggiero JE, Rughani J, Neiman J, Swanson S, Revol C, Green RJ. Real-world concordance of clinical practice with ASCO and NCCN guidelines for EGFR/ALK testing in aNSCLC. J Clin Oncol 35:8s, 2017(suppl; abstr 212).
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed bymultiregion sequencing. N Engl J Med 2012;366:883-92.
14. Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017;7:1-12.
15. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251-6.
16. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, IslamM, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov 2018;8:37-48.
17. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015;9:783-90.
18. Sacher AG, Komatsubara KM, Oxnard GR. Application of plasma genotyping technologies in non-small cell lung cancer: a practical review. J Thorac Oncol 2017;12:1344-56.
19. Kim ST, Banks KC, Lee S-H, Kim K, Park JO, Park SH, et al. Prospective feasibility study for using cell-free circulating tumor DNA-guided therapy in refractorymetastatic solid cancers: an interim analysis. JCO Precis Oncol 2017;1-15.
20. Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol 2017;12:258-68.
21. Schwaederle M, Patel SP, Husain H, Ikeda M, Lanman R, Banks KC, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 2017;23:5101-11.
22. Santos ES, Raez LE, Castillero LDCC, Marana C, Hunis B. Genomic tissue analysis and liquid biopsy profiles from patients diagnosed with advanced adenocarcinoma of the lung. Clin Oncol 2016;1:1-4.
23. Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, et al. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Res Treat 2017;164: 627-38.
24. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 2015;10:e0140712.
25. Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2016;2:1014-22.
26. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016;34:547-55.
27. Ulz P, Heitzer E, Geigl JB, Speicher MR. Patient monitoring through liquid biopsies using circulating tumor DNA. Int J Cancer 2017;141: 887-96.
28. Kennedy SR, SchmittMW,Fox EJ, Kohrn BF, Salk JJ, Ahn EH, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc 2014;9:2586-606.
29. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:9530-5.
30. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A 2012;109:14508-13.
31. Ahn J, Hwang B, Young Kim H, Jang H, Kim H-P, Han S-W, et al. Asymmetrical barcode adapter-assisted recovery of duplicate reads and error correction strategy to detect raremutations in circulating tumor DNA. Sci Rep 2017;7:46678.
32. Schmitt MW, Fox EJ, Prindle MJ, Reid-Bayliss KS, True LD, Radich JP, et al. Sequencing small genomic targets with high efficiency and extreme accuracy. Nat Methods 2015;12:423-5.
33. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, et al. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res 2018 Mar 29. [Epub ahead of print].
34. Kim ST, Lee W-S, Lanman RB, Mortimer S, Zill OA, Kim K-M, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel inmetastatic solid tumor patients. Oncotarget 2015;6:40360-9.
35. Zill OA, Mortimer S, Banks KC, Nagy RJ, Chudova D, Jackson C, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. J Clin Oncol 34:18s, 2016 (suppl; abstr LBA11501).
36. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23:703-13.
37. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016;48:607-16.
38. The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20.
39. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist 2016;21:762-70.
40. Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, et al. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget 2016;7:24172-8.
41. Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, et al. Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma. Eur Urol 2017;72:557-64.
42. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, et al. Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 2017;27:81-7.
43. LiangDH,Ensor JE, LiuZ-B,Patel A,PatelTA,Chang JC, et al.Cell-freeDNAas amolecular tool formonitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 2016;155:139-49.
44. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 2016;6:1352-65.
45. Schwaederlé M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016;7:9707-17.
46. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res 2016;22:5497-505.
47. Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, et al. Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer. J Thorac Oncol 2017;12:e81-4.
48. Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplifiedmetastatic breast cancer. Clin Cancer Res. 2017;23:5687-95.
49. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 2017;23: 5729-36.
50. Kuziora M, Ranade K. Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Abstract nr 582.
51. Kuziora M, Ranade K. Association of early reduction in circulating tumor DNA (ctDNA) with improved progression-free survival (PFS) and overall survival (OS) of patients (pts) with urothelial bladder cancer (UBC) treated with durvalumab (D). J Clin Oncol 35:15s, 2017 (suppl; abstr 11538).